Table 2.
Comparison of Visual Function and Patient-Reported Outcomes
| Control | Post-PRP PDR | Follow-up Minus Baselinea | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Assessments | Baseline | Follow-up | P value | Baseline | Follow-up | P value | Control | Post-PRP PDR | P value |
| Visual acuity (logMAR) | –0.07 ± 0.09 | –0.03 ± 0.10 | 0.866 | 0.18 ± 0.21 | 0.20 ± 0.28 | 0.580 | 0.04 ± 0.07 | 0.02 ± 0.18 | 0.866 |
| Pelli-Robson contrast sensitivity (log) | 1.76 ± 0.14 | 1.64 ± 0.09 | 0.070 | 1.44 ± 0.17 | 1.31 ± 0.21 | 0.012 | –0.12 ± 0.18 | –0.14 ± 0.22 | 0.853 |
| Reading acuity (logMAR) | –0.04 ± 0.05 | 0.19 ± 0.20 | < 0.001 | 0.23 ± 0.32 | 0.41 ± 0.22 | < 0.001 | 0.23 ± 0.19 | 0.18 ± 0.20 | 0.515 |
| FDP 24-2 (dB) | |||||||||
| MD | 0.73 ± 2.76 | 0.91 ± 1.84 | 0.820 | –7.20 ± 5.12 | –8.48 ± 6.23 | 0.371 | 0.18 ± 2.53 | –0.98 ± 4.76 | 0.459 |
| PSD | 2.53 ± 0.32 | 2.97 ± 0.75 | 0.019 | 5.74 ± 1.89 | 6.42 ± 1.78 | 0.020 | 0.44 ± 0.53 | –0.49 ± 5.72 | 0.317 |
| FS | 29.55 ± 5.72 | 30.00 ± 4.63 | 0.541 | 22.41 ± 1.89 | 23.86 ± 5.33 | 0.272 | 0.45 ± 4.78 | 1.07 ± 5.67 | 0.925 |
| HFA 10-2 (dB) | |||||||||
| MD | –0.04 ± 0.80 | –1.18 ± 1.50 | 0.009 | –4.08 ± 2.94 | –5.00 ± 3.19 | 0.170 | –1.14 ± 1.09 | –0.92 ± 3.07 | 0.370 |
| PSD | 1.25 ± 0.58 | 1.20 ± 0.24 | 0.750 | 3.02 ± 2.20 | 3.19 ± 2.88 | 0.728 | –0.05 ± 0.48 | 0.17 ± 2.96 | 0.852 |
| FS | 36.50 ± 2.64 | 34.60 ± 2.41 | 0.012 | 30.38 ± 6.05 | 28.62 ± 5.38 | 0.039 | –1.90 ± 1.91 | –1.76 ± 6.76 | 0.950 |
| HFA 60-4 total threshold (dB) | 1149 ± 117 | 1042 ± 173 | 0.027 | 230 ± 203 | 201 ± 209 | 0.572 | –97.92 ± 133.61 | –17.43 ± 112.43 | 0.108 |
| Dark adaptation (min) | 8.85 ± 1.69 | 9.01 ± 4.51 | 0.706 | 13.54 ± 5.75 | 15.14 ± 8.83 | 0.619 | 0.71 ± 0.71 | 1.59 ± 6.48 | 0.977 |
| LLQ composite score | 97.5 ± 2.4 | 93.7 ± 5.9 | 0.102 | 62.7 ± 22.1 | 62.0 ± 20.9 | 0.819 | –3.77 ± 6.96 | –0.63 ± 12.47 | 0.447 |
| NEI-VFQ composite score | 97.8 ± 1.4 | 94.7 ± 5.0 | 0.067 | 77.7 ± 15.5 | 76.6 ± 18.5 | 0.618 | –3.06 ± 4.94 | –1.14 ± 10.32 | 0.567 |
FS, foveal sensitivity; MD, mean deviation; PSD, pattern standard deviation.
After 5 years, diabetic patients treated with PRP had age-related decreases in vision, which were comparable with those seen in the control participants. These patients also had stable quality of life despite poor vision.
a
Compared the extent of vision loss and change in patient-reported outcomes over time between the control and diabetic patients.